Interstitial Lung Disease Clinical Trials in Dallas, Texas

4 studies are recruiting for interstitial lung disease in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

   This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

   Stage

   Not phased

   Ages

   18 and older

   Site

   Baylor University Medical Center, Dallas, Texas

   Locations

   71 in total

   Run by

   United Therapeutics

   See if you can join NCT06388421 on ClinicalTrials.gov

2. PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

   This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosi…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   University of Texas Southwestern, Dallas, Texas

   Locations

   24 in total

   Run by

   University of Massachusetts, Worcester

   See if you can join NCT06855329 on ClinicalTrials.gov

3. Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

   Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Baylor University Medical Center, Dallas, Texas

   Locations

   165 in total

   Run by

   United Therapeutics

   See if you can join NCT05943535 on ClinicalTrials.gov

4. Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

   This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improv…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   aTyr Investigative Site, Dallas, Texas

   Locations

   15 in total

   Run by

   aTyr Pharma, Inc.

   See if you can join NCT05892614 on ClinicalTrials.gov